🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)

    RFA-DA-23-008

    National Institutes of Health

    Opening date 16 May 2022, 12:00AM

    Closing date 12 Nov 2024, 12:00AM

    Funding Opportunity Number: RFA-DA-23-008

    Opportunity Category: Discretionary

    CFDA Number(s): 93.279 -- Drug Abuse and Addiction Research Programs

    Cost Sharing or Matching Requirement: No

    Posted Date: May 16, 2022 12:00:00 AM EDT

    Closing Date: Nov 12, 2024 12:00:00 AM EST

    Award Ceiling: $400000

    Award Floor: none

    Eligible Applicants: Independent school districts,Private institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),Public housing authorities/Indian housing authorities,Native American tribal governments (Federally recognized),State governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,Public and State controlled institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Special district governments,For profit organizations other than small businesses,City or township governments,County governments

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: Stimulant use has been increasing among opioid users since 2016, based on overdose data and this makes control of the opioid epidemic more difficult, as it occurs in addition to the continuing influx of fentanyl and related compounds. Stimulant/opioid users present unfamiliar clinical issues to providers and experienced providers often find polysubstance users less motivated to address stimulant use. Stimulant use also has continued to account for a substantial fraction of HIV cases among gay men and other MSM. Much of this use is problematic/episodic (meth, cocaine, ketamine) and does not rise to the level of SUD or represents mild SUD despite problematic practices (syringe sharing, unprotected sex, etc.). We have limited tools for stimulant treatment and even fewer tools for addressing non-SUD or mild SUD stimulant use. New initiatives should incorporate new treatments as they become available. Particular attention is needed re: stimulant use in the context of polysubstance use that includes opioids including identification of motivations and contexts for more effectively implementing intervention.

    Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept